Loading clinical trials...

Acute Exercise on Neurocognitive Function Among Adults With/Without Generic Risk of AD | Clinical Trials | Clareo Health

COMPLETEDNA

Acute Exercise on Neurocognitive Function Among Adults With/Without Generic Risk of AD

Acute Exercise Effect on Neurocognitive Function Among Cognitively Normal Late-Middle-Aged Adults With/Without Generic Risk of Alzheimer's Disease: The Moderation Role of Exercise Volume and Apolipoprotein E Genotype

NCT05591313•National Taiwan Normal University

View on ClinicalTrials.gov

Summary

This study explores the acute exercise effect on neurocognitive function and also its potential moderators in an exercise setting and Apolipoprotein E (APOE) genetic risk.

Detailed Description

Acute exercise has emerged as a modifier to multiple aspects of cognitive function; however, its effect on populations with different risks of Alzheimer's disease (AD) and the role of exercise variance and APOE genotype within the effect reminds underestimated. The current study aimed to examine the acute exercise effect on neurocognitive function from behavioral and neuroelectric perspectives among cognitively normal late-middle-aged adults. Additionally, we determined whether variations in exercise intensity and duration and the presence of the APOE ɛ4 allele modulated the effect.

Eligibility

Age

50 - 70 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Adults aged between 50 and 70 years old
•2. Normal or corrected-to-normal vision based on the minimal 20/20 standard
•3. Cognitively normal as mini-mental state examination scores (MMSE) \> 26

Exclusion Criteria

•1. Neurological or psychiatric disorders
•2. Cardiovascular disease
•3. Risk of cardiovascular fitness assessment based on the Physical Activity Readiness Questionnaire (PAR-Q)
•4. Red-green color blindness.

Locations (1)

Department of Physical Education and Sport Sciences, National Taiwan Normal University

Taipei, Taiwan

Key Dates

Start Date

May 17, 2016

Primary Completion Date

September 26, 2019

Completion Date

September 26, 2019

Last Updated

February 8, 2023

Enrollment

ACTUAL participants

Conditions

Alzheimer Disease 2 Due to Apoe4 Isoform

Interventions

LI-40

BEHAVIORAL

MI-30

BEHAVIORAL

HI-16

BEHAVIORAL

Dementia Risk and Dynamic Response to Exercise

NCT04009629

Alzheimer Disease 2 Due to Apoe4 IsoformHealthy Aging

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 8, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions